Evidence map›Paper›PMID 30250044›Full record

ArticleScientific reports2018

Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor.

Chong Li, Jing Cao, Ning Zhang, Meiqing Tu, Fengwei Xu, Shuang Wei, Xiaojing Chen, Yuhong Xu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  15. Effects of the Wnt/Contrast media & molecular imaging · 2022
    Article
  16. Review
  17. Review
  18. Wnt/β-catenin signaling in cancers and targeted therapies.Signal transduction and targeted therapy · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chong LiPharmacy School, Shanghai Jiaotong University, Shanghai, 200240, China.
Jing CaoPharmacy School, Shanghai Jiaotong University, Shanghai, 200240, China.
Ning ZhangPharmacy School, Shanghai Jiaotong University, Shanghai, 200240, China.
Meiqing TuPharmacy School, Shanghai Jiaotong University, Shanghai, 200240, China.
Fengwei XuPharmacy School, Shanghai Jiaotong University, Shanghai, 200240, China.
Shuang WeiPharmacy School, Shanghai Jiaotong University, Shanghai, 200240, China.
Xiaojing ChenPharmacy School, Shanghai Jiaotong University, Shanghai, 200240, China.
Yuhong XuPharmacy School, Shanghai Jiaotong University, Shanghai, 200240, China. yhxu@sjtu.edu.cn.ORCID 0000-0001-5302-6392
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancers are driven by a variety of somatic gene mutations and identifying these mutations enables the development of novel target drugs. We have sought to identify abnormalities in Wnt pathway-related genes that are sensitive to Wnt inhibitor treatment. We examined Patient Derived Xenograft (PDX) RNA samples and found new R-Spondin 2 (RSPO2) transcript fusions with the EMC2, PVT1 or HNF4G genes. These fusion events were identified in about 1.4% of the digestive system cancer samples. We then examined the oncogenic effects of the RSPO2-EMC2 fusion gene and confirmed that it can drive oncogenesis, sustain tumor growth and promote metastasis. Finally, we used a Wnt pathway Porcupine inhibitor CGX1321 to treat PDX mouse models containing RSPO2 fusion genes. All the RSPO2 fusion tumors responded to the treatment and stopped progression. Our data show that Wnt pathway inhibition could provide an effective treatment for cancers containing RSPO2 fusion. The RSPO2 fusion will serve as a good biomarker for screening patients to support clinical treatment of digestive system cancers using Wnt pathway inhibitors.

Indexed as

AcyltransferasesAnimalsbeta CateninCarcinogenesisCell ProliferationHEK293 CellsHepatocyte Nuclear Factor 4HeterograftsHumansIntercellular Signaling Peptides and ProteinsMembrane ProteinsMiceMutationNeoplasmsOncogene Proteins, FusionPlasmidsAcyltransferasesbeta CateninEMC2 protein, humanHepatocyte Nuclear Factor 4HNF4G protein, humanIntercellular Signaling Peptides and ProteinsMembrane ProteinsOncogene Proteins, FusionPORCN protein, humanPVT1 long-non-coding RNA, humanRNA, Long NoncodingRspo2 protein, humanR-Spondins

Identifiers

PMID30250044
PMCPMC6155119
OpenAlexW2891828924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.